|
Baseline levofloxacin MIC, μg/mL
|
Microbiological eradication, n/N (%)
|
Clinical cure, n/N (%)
|
|---|
|
≤0.015
|
9/10 (90.0)
|
10/10 (100)
|
|
0.03
|
120/126 (95.2)
|
124/126 (98.4)
|
|
0.06
|
38/40 (95.0)
|
37/40 (92.5)
|
|
0.125
|
9/11 (81.8)
|
10/11 (90.9)
|
|
0.25
|
6/8 (75.0)
|
8/8 (100)
|
|
0.5
|
14/17 (82.4)
|
17/17 (100)
|
|
1
|
5/6 (83.3)
|
6/6 (100)
|
|
2
|
1/1 (100)
|
0/1 (0)a
|
|
4
|
3/9 (33.3)
|
9/9 (100)
|
|
8
|
11/17 (64.7)
|
15/17 (88.2)
|
|
16
|
20/44 (45.5)
|
36/44 (81.8)
|
|
32
|
4/13 (30.8)
|
11/13 (84.6)
|
|
64
|
1/6 (16.7)
|
4/6 (66.7)
|
|
128
|
0/1 (0)
|
0/1 (0)
|
- ME microbiologically evaluable, MIC minimum inhibitory concentration, n number of isolates assigned to an outcome of eradication or clinical cure, N number of isolates at each levofloxacin MIC
- Four E. coli isolates were not retested to determine MIC end points and were excluded from this analysis. Five patients had 2 Enterobacteriaceae isolates identified at baseline. Four patients had a clinical response of cure, and 1 patient had a clinical response of failure. Clinical response for these patients was counted once for each isolate at its respective MIC
- a This isolate was present in combination with a second isolate that had a levofloxacin MIC of 16 μg/mL; the patient’s clinical response was failure
